CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: Clinicopathologic features and comparison with plasma cell myeloma

Horatiu Olteanu, Alexandra M. Harrington, Steven H. Kroft

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

The majority of plasma cell myelomas (PCMs) are positive for CD200, a membrane protein with immunosuppressive function. There are no flow cytometry data in the literature on plasma cell CD200 expression in other immunoproliferative disorders. Therefore we used flow cytometry to study the expression of CD200 on plasma cells in diagnostic bone marrow aspirates from 61 patients with monoclonal gammopathy of undetermined significance (MGUS) and 10 patients with lymphoplasmacytic lymphoma (LPL). For comparison, we evaluated CD200 expression in 74 PCM bone marrow biopsies. Thirty-three (54.1%) of 61 MGUS cases and 2 (20.0%) of 10 LPL cases were CD200+. Comparative clinicopathologic parameters for MGUS cases, based on CD200 expression status, showed no differences between the 2 groups. The proportion of CD200+ PCMs (73.0%) in our series was significantly higher than that of CD200+ MGUS (P = .030) and CD200+ LPL (P = .002) cases.

Original languageEnglish (US)
Pages (from-to)867-876
Number of pages10
JournalAmerican journal of clinical pathology
Volume138
Issue number6
DOIs
StatePublished - Dec 1 2012

Keywords

  • CD200
  • Flow cytometry
  • Immunophenotype
  • Lymphoplasmacytic lymphoma
  • MGUS

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: Clinicopathologic features and comparison with plasma cell myeloma'. Together they form a unique fingerprint.

  • Cite this